Merck Serono S. A.

Phenex Pharmaceuticals Ag

Phenix Pharmaceuticals Ag

Hochschule Biberach

Kerstin Otte

Andreas Goutopoulos

Meinolf Thiemann

Matthias Schwarz

Achim Feurer

Renate Sekul

Xuliang Jiang

Ulrich Abel

Holger Deppe

Ulrich Grädler

John S Kiely

Claus Kremoser

Ronnie C Hanecak

Elena Dneprovskaia

Ulrich Deuschle

Tim Gahman

Kristina Giegrich

Normand Hébert

Ingo Kober

Manfred Kögl

Harald Kranz

Matthew Lee

Carlton Sage

Manish Sud

Ulrike Bauer

Zach Cheruvallath

Ulrich Graedler

René Handrick

Simon Fischer

The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

3-arylamino pyridine derivatives

The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. 

The invention provides compounds according to the general formula () which bind to the NRHreceptor and act as agonists, antagonists or mixed agonists/antagonists of the NRHreceptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.

FXR NR1H4 nuclear receptor binding compounds

The present invention relates to compounds according to the general formula (I) which bind to the nuclear receptor, NR1H4, and act as agonists and antagonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds.

NR1H4 nuclear receptor binding compounds

The present invention relates to compounds according to the general formula (I) which bind to the NR1H4 receptor and act as agonists of the NR1H4 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.

Growing community of inventors

Heidelberg, Germany

Kerstin Otte